Dr. Michael H. Rivner, MD
Neurology (Clinical Neurophysiology Physician)
- Medicare participating
At a glance
- Medical school
- Duke University School of Medicine (1978)
- Years since graduation
- 48
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 168
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1978Medical school: Duke University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Clinical Neurophysiology Physician primary
GA license 020806 -
Neurology Physician
GA license 020806
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Wellstar Mcg Health, Affiliated With Med Col Augusta, GA
- Atrium Health Navicent the Medical Center Macon, GA
Medical groups
- Wellstar Medical Group LLC (3,093 clinicians)
- Health Services of Central Georgia (300 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 168
- Services billed
- 640
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 183 | 108 |
| Needle measurement of electrical activity in muscle with injection of chemical for paralysis of nerve muscle | 65 | 26 |
| Established patient office or other outpatient visit, 30-39 minutes | 40 | 35 |
| Needle measurement of electrical activity in arm or leg muscles, limited study | 34 | 27 |
| Injection of chemical for paralysis of nerve muscles on side of neck excluding voice box | 32 | 12 |
| Injection of chemical for paralysis of nerve muscles on side of face | 28 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 17 | 17 |
| Nerve conduction, 5-6 studies | 15 | 15 |
| Needle measurement of electrical activity in arm or leg muscles, complete study | 14 | 13 |
| Nerve conduction, 3-4 studies | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Radicava Ors (edaravone) | 189 |
| Methotrexate (methotrexate sodium) Other prescribers in Macon, GA | 136 |
| Baclofen Other prescribers in Macon, GA | 90 |
| Riluzole | 89 |
| Privigen (immun glob g(igg)/pro/iga 0-50) | 84 |
| Pyridostigmine Bromide Other prescribers in Macon, GA | 82 |
| Prednisone Other prescribers in Macon, GA | 72 |
| Gabapentin Other prescribers in Macon, GA | 69 |
| Gamunex-C (immune globul g/gly/iga avg 46) | 66 |
| Glycopyrrolate Other prescribers in Macon, GA | 52 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 8 companies reported 80 payments worth $77,534 in total to this clinician.
| Argenx US, Inc. | $23,118 |
|---|---|
| UCB, Inc. | $19,066 |
| Janssen Biotech, Inc. | $18,266 |
| Alexion Pharmaceuticals, Inc. | $16,832 |
| AbbVie Inc. | $110 |
| Pfizer Inc. | $106 |
| AstraZeneca Pharmaceuticals LP | $18.53 |
| Tanabe Pharma America, Inc. | $18.05 |
| Compensation for services other than consulting (speaking, faculty) | $65,681 |
|---|---|
| Travel and Lodging | $8,948 |
| Food and Beverage | $1,865 |
| Consulting Fee | $1,040 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Argenx US, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $7,500 |
| UCB, Inc. Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $6,000 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $5,900 |
| Argenx US, Inc. Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $5,625 |
| Alexion Pharmaceuticals, Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,720 |
| UCB, Inc. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $4,500 |
| Janssen Biotech, Inc. Sep 27, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,885 |
| Janssen Biotech, Inc. Dec 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,885 |
| Janssen Biotech, Inc. Jul 12, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,885 |
| Argenx US, Inc. Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $3,750 |
All 44 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| UCB, Inc. Dec 26, 2025 | Consulting Fee Rystiggo · Neurology | $1,040 |
| Janssen Biotech, Inc. Dec 13, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,885 |
| Janssen Biotech, Inc. Dec 9, 2025 | Travel and Lodging travel to ALPHARETTA, GA · in-kind | $1,806 |
| Alexion Pharmaceuticals, Inc. Dec 4, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $2,950 |
| Alexion Pharmaceuticals, Inc. Nov 4, 2025 | Travel and Lodging travel to Augusta, GA | $2.80 |
| Janssen Biotech, Inc. Oct 2, 2025 | Travel and Lodging travel to AVENTURA, FL | $3.08 |
| Janssen Biotech, Inc. Sep 27, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,885 |
| Janssen Biotech, Inc. Sep 27, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,498 |
| Janssen Biotech, Inc. Sep 25, 2025 | Travel and Lodging travel to CORAL GABLES, FL · in-kind | $515 |
| Argenx US, Inc. Sep 18, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $3,750 |
| Argenx US, Inc. Aug 26, 2025 | Travel and Lodging VYVGART · Immunology · travel to Atlanta, GA | $1,312 |
| Argenx US, Inc. Aug 26, 2025 | Travel and Lodging VYVGART · Immunology · travel to Atlanta, GA | $15.00 |
| UCB, Inc. Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $3,000 |
| UCB, Inc. Aug 21, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Augusta, GA | $2.66 |
| Argenx US, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $7,500 |
| Argenx US, Inc. Jul 24, 2025 | Travel and Lodging VYVGART · Immunology · travel to Greenville, SC | $241 |
| Argenx US, Inc. Jul 14, 2025 | Travel and Lodging VYVGART · Immunology · travel to Greenville, SC | $203 |
| Argenx US, Inc. Jul 14, 2025 | Travel and Lodging VYVGART · Immunology · travel to Greenville, SC | $25.00 |
| Janssen Biotech, Inc. Jul 12, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,885 |
| Janssen Biotech, Inc. Jul 12, 2025 | Travel and Lodging travel to CHICAGO, IL | $322 |
| Argenx US, Inc. Jun 30, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $625 |
| Janssen Biotech, Inc. Jun 27, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $605 |
| Janssen Biotech, Inc. Jun 27, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $227 |
| Janssen Biotech, Inc. Jun 27, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $217 |
| Argenx US, Inc. Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) VYVGART · Immunology | $5,625 |
| Argenx US, Inc. Jun 23, 2025 | Travel and Lodging VYVGART · Immunology · travel to Memphis, TN | $318 |
| UCB, Inc. Jun 13, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $6,000 |
| Argenx US, Inc. May 17, 2025 | Travel and Lodging VYVGART · Immunology · travel to Memphis, TN | $697 |
| Argenx US, Inc. May 17, 2025 | Travel and Lodging VYVGART · Immunology · travel to Memphis, TN | $155 |
| Argenx US, Inc. May 17, 2025 | Travel and Lodging VYVGART · Immunology · travel to Memphis, TN | $55.00 |
| Alexion Pharmaceuticals, Inc. May 8, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $4,720 |
| UCB, Inc. May 6, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Valdosta, GA · in-kind | $1,131 |
| Alexion Pharmaceuticals, Inc. May 5, 2025 | Travel and Lodging travel to Atlanta, GA | $210 |
| UCB, Inc. May 5, 2025 | Travel and Lodging Rystiggo · Neurology · travel to Valdosta, GA · in-kind | $15.00 |
| Argenx US, Inc. Apr 25, 2025 | Compensation for services other than consulting (speaking, faculty) | $2,188 |
| Alexion Pharmaceuticals, Inc. Mar 27, 2025 | Compensation for services other than consulting (speaking, faculty)Company’s descriptionSpeaker Fee | $1,770 |
| UCB, Inc. Mar 20, 2025 | Compensation for services other than consulting (speaking, faculty) Zilbrysq · Neurology | $3,000 |
| UCB, Inc. Mar 20, 2025 | Travel and Lodging Zilbrysq · Neurology · travel to Augusta, GA · in-kind | $2.80 |
| Alexion Pharmaceuticals, Inc. Feb 27, 2025 | Compensation for services other than consulting (speaking, faculty) ULTOMIRIS · Rare Disease Company’s descriptionSpeaker Fee | $5,900 |
| Alexion Pharmaceuticals, Inc. Feb 8, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Nashville, TN · in-kind Company’s descriptionSpeaker Expenses | $223 |
| Alexion Pharmaceuticals, Inc. Feb 8, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Atlanta, GA | $211 |
| Alexion Pharmaceuticals, Inc. Feb 8, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Atlanta, GA | $22.58 |
| Alexion Pharmaceuticals, Inc. Feb 7, 2025 | Travel and Lodging ULTOMIRIS · Rare Disease · travel to Nashville, TN · in-kind Company’s descriptionSpeaker Expenses | $413 |
| UCB, Inc. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) Rystiggo · Neurology | $4,500 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 6 industry-funded studies in 2025, from 3 companies. The companies reported $57,493 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blinded, placebo-controlled, phase 3, parallel group design study evaluating the efficacy and safety of efgartigimod IV in adult participants with acetylcholine receptor binding antibody (AChR-Ab)…
Argenx US, Inc. - Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
UCB SA · Completed · NCT04225871 - A Phase 3b, Randomized, Open-Label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis
Argenx US, Inc. - A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
Alexion Pharmaceuticals, Inc. - An Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Zilucoplan in Participants With Generalized Myasthenia Gravis Who Were Previously Receiving Intravenous Complement Component 5 Inhibitors
UCB SA · Completed · NCT05514873 - Long Term, Observational, Registry of Patients With Generalized Myasthenia Gravis Who Have Received Treatment With Complement C5 Inhibition Therapies
Alexion Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.